Adam Kashishian
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 12
- Immunology top 5%
- Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 22
- Protein Kinase Regulation and GTPase Signaling 11
- Protein Tyrosine Phosphatases 4
- DNA Repair Mechanisms 3
- Oncology top 5%
- Cancer-related Molecular Pathways 6
- Cytokine Signaling Pathways and Interactions 3
- Hematology top 5%
-
- Lymphoma Diagnosis and Treatment 5
- Co-authors
- Jonathan A. CooperAndrius KazlauskasJoseph SchlessingerRiko NishimuraBrian J. LannuttiSarah MeadowsMindaugas ValiusAndreas Batzer
- Cited by
- GeneticsImmunologyMolecular Biology
- Partner nations
- United StatesGermanySouth Africa
In The Last Decade
Adam Kashishian
32 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Genetics 664
- Immunology 687
- Molecular Biology 2.2k
- Oncology 769
- Hematology 294
Countries citing papers authored by Adam Kashishian
This map shows the geographic impact of Adam Kashishian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Kashishian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Kashishian more than expected).
Fields of papers citing papers by Adam Kashishian
This network shows the impact of papers produced by Adam Kashishian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Kashishian. The network helps show where Adam Kashishian may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Adam Kashishian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 1 | |
| 2 | 2017 | 27 | |
| 3 | 2013 | 36 | |
| 4 | 2012 | 69 | |
| 5 | 2012 | 1 | |
| 6 | 2010 | 13 | |
| 7 | CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilitybreakdown → | 2010 | 588 |
| 8 | 2009 | 6 | |
| 9 | 2008 | 4 | |
| 10 | 2005 | 101 | |
| 11 | DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. | 2003 | 75 |
| 12 | 1998 | 76 | |
| 13 | 1997 | 210 | |
| 14 | 1994 | 415 | |
| 15 | 1993 | 18 | |
| 16 | 1993 | 64 | |
| 17 | 1993 | 38 | |
| 18 | 1993 | 59 | |
| 19 | 1992 | 36 | |
| 20 | 1992 | 212 |
About Adam Kashishian
Adam Kashishian is a scholar working on Genetics, Oncology and Molecular Biology, having authored 32 papers that have together received 2.9k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (22 papers), Chronic Lymphocytic Leukemia Research (12 papers), Protein Kinase Regulation and GTPase Signaling (11 papers), Cancer-related Molecular Pathways (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Protein Tyrosine Phosphatases (4 papers), DNA Repair Mechanisms (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). The work is most often cited by research in Genetics (664 citations), Immunology (687 citations) and Molecular Biology (2.2k citations). Adam Kashishian has collaborated with scholars based in United States, Germany and South Africa. Frequent co-authors include Jonathan A. Cooper, Andrius Kazlauskas, Joseph Schlessinger, Riko Nishimura, Brian J. Lannutti, Sarah Meadows, Mindaugas Valius, Andreas Batzer, Wei Li and Bart Steiner. Their work appears in journals such as Journal of Biological Chemistry, The EMBO Journal and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.